ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Phenytoin

Also written as “Phenytoin (Ascoli)”, “Dilantin Infatabs (Phenytoin)” and “Phenytoin: Study Drug”.

Its studies are mostly in Epilepsy · Seizures · Hepatitis C, led by 8 companies.

Drug pagePhenytoin: every studyMany companies study it; this page follows only the 10 they lead. All 42 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Apr 20, 201010 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only30 open or runningphase 1since Apr 20, 2010Apr 20, 2010none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Feb 20, 2008Feb 20, 2008none ahead
Janssen Infectious Diseases BVBAits history only10 open or runningphase 1since Jul 4, 2012Jul 4, 2012none ahead
Johnson & Johnsonits history only10 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
Merckits history only10 open or runningphase 1since Mar 25, 2025Mar 25, 2025none ahead
Novartisits history only11 open or runningphase 1since Aug 18, 2026Aug 18, 2026none ahead
Pfizerits history only10 open or runningphase 1since Jun 14, 2024Jun 14, 2024none ahead
Zydus Lifesciences10 open or runningphase 1since Jun 23, 2021Jun 23, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zydus Lifesciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 23, 2021First study: phase 1 study in HealthyFirst studyNCT04981704 · 74 enrolled · United States

TargetBeta

“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
QuinidineruleOtsukaphase 317
rufinamideruleEisaiphase 37

Studies

The one study Zydus Lifesciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04981704Healthy · United States1CompletedJun 30, 202174

How it is read

Names in the registry

  • “Phenytoin”, 5 entries
  • “Phenytoin (Ascoli)”, 1 entry
  • “Dilantin Infatabs (Phenytoin)”, 1 entry
  • “Phenytoin: Study Drug”, 1 entry
  • “phenytoin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.